Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,440 stopped studies mapped to Adenocarcinoma and descendants · 92% state a reason
Over the 1,440 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT06361810 | PSMA Therapy and Immunotherapy in Kidney Cancer | Phase 1 / Phase 2 | withdrawn | Apr 12, 2024 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | funding withdrawn | Funding |
| NCT07011849 | Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain… | Phase 2 | withdrawn | Jun 10, 2025 | M.D. Anderson Cancer Center | 0 participants | Other (stated, no rule matched) |
| NCT04159155 | A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer(CAN-STAMP) | Phase 2 / Phase 3 | terminated | Nov 12, 2019 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT05975645 | A Clinical Study of TQB2618 Injection Combined With Penpulimab Injection and Anlotinib… | Phase 1 | terminated | Aug 4, 2023 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | This study was closed due to business reasons. Closure was not prompted by any safety or efficacy… | Safety / toxicity |
| NCT04336943 | Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a… | Phase 2 | terminated | Apr 7, 2020 | University of Washington | Slow accrual | Enrollment / accrual |
| NCT04141995 | FOLFIRINOX With Digoxin in Patients With Resectable Pancreatic Cancer | Phase 2 | terminated | Oct 28, 2019 | University of Nebraska | Due to low accrual and futility | Efficacy / futility |
| NCT02070705 | DCE MRI in Patients With Pancreatic Cancer | N/A | terminated | Feb 25, 2014 | OHSU Knight Cancer Institute | Loss of funding | Funding |
| NCT03729596 | MGC018 With or Without MGA012 in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Nov 2, 2018 | MacroGenics | Business decision | Sponsor / business decision |
| NCT05435352 | Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast…(PEAR-TNBC) | — | terminated | Jun 28, 2022 | Ourotech, Inc. | Lack of funding | Funding |
| NCT05678205 | A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With… | Phase 1 / Phase 2 | withdrawn | Jan 10, 2023 | Artiva Biotherapeutics, Inc. | Corporate business decision | Sponsor / business decision |
| NCT03316872 | Study of Pembrolizumab and Radiotherapy in Liver Cancer | Phase 2 | terminated | Oct 20, 2017 | University Health Network, Toronto | The study was stopped due to the shift in systemic treatment paradigm for HCC precluding further… | Enrollment / accrual |
| NCT06299163 | NM32-2668 in Adult Patients With Selected Advanced Solid Tumors | Phase 1 | terminated | Mar 7, 2024 | Numab Therapeutics AG | Business decision | Sponsor / business decision |
| NCT04042051 | Copanlisib in Combination With T-DM1 in Pretreated Unresectable Locally Advanced or…(Panthera) | Phase 1 | terminated | Aug 1, 2019 | Cancer Trials Ireland | Accrual rate to date was too low to finish the trial in a reasonable timeframe | Enrollment / accrual |
| NCT05300958 | Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer | Phase 2 | terminated | Mar 29, 2022 | Sun Yat-sen University | Difficulty accruing subjects the study accrual was closed. | Enrollment / accrual |
| NCT06246786 | Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer) | Early Phase 1 | withdrawn | Feb 7, 2024 | Virginia G. Kaklamani | Unable to enroll to study. | Enrollment / accrual |
| NCT02140021 | Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer… | N/A | terminated | May 16, 2014 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT04116320 | Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors(AM-003) | Phase 1 | terminated | Oct 4, 2019 | Craig L Slingluff, Jr | Unable to enroll enough patients to complete targeted enrollment in a reasonable time. | Enrollment / accrual |
| NCT04577963 | A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Oct 8, 2020 | Hutchmed | At the time of study termination, both fruquintinib and tislelizumab are commercially available in… | Other (stated, no rule matched) |
| NCT04992507 | Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study | Phase 2 | terminated | Aug 5, 2021 | Ohio State University Comprehensive Cancer Center | Principal investigator departed sponsoring organization | Investigator |
| NCT05563272 | 89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors(STARBURST) | Phase 2 | terminated | Oct 3, 2022 | Telix Pharmaceuticals (Innovations) Pty Ltd | Indication scouting for TLX250-CDx will continue in theranostic studies, with a therapeutic… | Other (stated, no rule matched) |
| NCT01722890 | CharactHer. ICORG 12-09, V3 | — | terminated | Nov 7, 2012 | Cancer Trials Ireland | As per the HRBs new funding model, HRBs investment will not support costs associated with routine… | Funding |
| NCT03432897 | BrUOG 337: Olaparib Prior to Radical Prostatectomy For Advanced Prostate Cancer Defects…(337) | Phase 2 | terminated | Feb 14, 2018 | Brown University | Lack of enrollment secondary to eligibility criteria | Enrollment / accrual |
| NCT05511844 | Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors | Phase 1 | terminated | Aug 23, 2022 | Orum Therapeutics USA, Inc. | Sponsor Decision | Sponsor / business decision |
| NCT06590558 | Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a… | Phase 1 | withdrawn | Sep 19, 2024 | National Cancer Institute (NCI) | Manually added per CS0177524- Weekly CTEP status report. | Other (stated, no rule matched) |
| NCT04520906 | To Evaluate the Safety and Efficacy of Microwave Ablation Therapy in Patients With… | N/A | terminated | Aug 20, 2020 | Suzhou Hengruihongyuan Medical Technology Co. LTD | Obtaining medical device market approval through the predicate device comparison route. | Other (stated, no rule matched) |
| NCT05274451 | A Study to Investigate LYL797 in Adults With Solid Tumors | Phase 1 | terminated | Mar 10, 2022 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT05891197 | A Biomarker Screening Protocol for Participants With Solid Tumors(START) | — | terminated | Jun 6, 2023 | Lyell Immunopharma, Inc. | Pipeline Reprioritization | Other (stated, no rule matched) |
| NCT03469011 | A Study to Try to Bring Back Radioiodine Sensitivity in Patients With Advanced Thyroid… | Phase 1 | terminated | Mar 19, 2018 | AHS Cancer Control Alberta | Lack of Accrual | Enrollment / accrual |
| NCT04688333 | iConquerFear Program for the Treatment of Fear of Cancer Recurrence in Patients With… | — | withdrawn | Dec 30, 2020 | City of Hope Medical Center | Feasibility | Other (stated, no rule matched) |
| NCT05432193 | FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry… | Phase 1 | terminated | Jun 27, 2022 | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | Business decision | Sponsor / business decision |
| NCT06707896 | TCR1020-CD8 T Cells in KRAS-mutated Cancers | Phase 1 | withdrawn | Nov 27, 2024 | University of Pennsylvania | Administrative decision | Other (stated, no rule matched) |
| NCT05630937 | Study on Safety and Efficacy of NMS-01940153E in Adult Patients With Unresectable… | Phase 1 / Phase 2 | terminated | Nov 30, 2022 | Nerviano Medical Sciences | In the Phase II part of the study, among the participants evaluable for efficacy, no objective… | Efficacy / futility |
| NCT05634577 | A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With… | Phase 2 | terminated | Dec 2, 2022 | M.D. Anderson Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05161572 | Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally…(NeoRacing) | Phase 2 | terminated | Dec 17, 2021 | Fudan University | Difficult in recruiting participants | Enrollment / accrual |
| NCT06728657 | Preoperative HFRT Verses PULSAR for Locally Advanced GEJ or Proximal Gastric…(TORCH-G) | Phase 2 | suspended | Dec 11, 2024 | Fudan University | Difficult in recruiting participants | Enrollment / accrual |
| NCT05447910 | Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative… | — | terminated | Jul 7, 2022 | Mayo Clinic | insufficient funding | Funding |
| NCT05041101 | Grapiprant and Eribulin for the Treatment of Metastatic Inflammatory Breast Cancer | Phase 1 / Phase 2 | terminated | Sep 10, 2021 | M.D. Anderson Cancer Center | Termination was requested by study supporter IKENA oncology | Other (stated, no rule matched) |
| NCT05342350 | International Study of High-Risk Patients for Hepatocellular Carcinoma Using Liquid Biopsy(STOP-HCC) | — | terminated | Apr 22, 2022 | Johns Hopkins University | PI moving on from current institution | Other (stated, no rule matched) |
| NCT03094169 | AVID100 in Advanced Epithelial Carcinomas | Phase 1 / Phase 2 | terminated | Mar 29, 2017 | Formation Biologics | lack of efficacy | Efficacy / futility |
| NCT06067061 | "neoBREASTIM": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting…(neoBREASTIM) | Phase 1 / Phase 2 | terminated | Oct 4, 2023 | Institut Curie | insufficient recruitment | Enrollment / accrual |
| NCT04727151 | TAC T-cells for the Treatment of HER2-positive Solid Tumors(TACTIC-2) | Phase 1 / Phase 2 | terminated | Jan 27, 2021 | Triumvira Immunologics, Inc. | Study terminated by Sponsor for commercial reasons | Other (stated, no rule matched) |
| NCT05067842 | Circulating Tumor DNA (ctDNA) in Locally Advanced Esophageal and Gastroesophageal (GE)…(TRACT DNA) | — | withdrawn | Oct 5, 2021 | Medical College of Wisconsin | Low accrual and PI leaving institution | Enrollment / accrual |
| NCT02446860 | A Study of Anti-PD1 (Nivolumab) Therapy as Pre- and Post-operative Therapy in Metastatic…(ADAPTeR) | Phase 2 | terminated | May 18, 2015 | Royal Marsden NHS Foundation Trust | The study was unable to recruit the target number of patients (enrolled 15 instead of 19) and did… | Enrollment / accrual |
| NCT06592664 | Certepetide Phase 1b/2a Continuous Infusion Trial in mPDAC(FORTIFIDE) | Phase 1 / Phase 2 | withdrawn | Sep 19, 2024 | Lisata Therapeutics, Inc. | Management Decision | Other (stated, no rule matched) |
| NCT04148378 | A Pilot Study to Explore the Role of Gut Flora in Colorectal Cancer | — | withdrawn | Nov 1, 2019 | ProgenaBiome | Company shifted focus | Sponsor / business decision |
| NCT05603572 | KAT-101 in Subjects With Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | suspended | Nov 2, 2022 | Primocure Pharma | Enrollment paused | Enrollment / accrual |
| NCT02419495 | Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple… | Phase 1 | terminated | Apr 17, 2015 | M.D. Anderson Cancer Center | Administratively Complete | Other (stated, no rule matched) |
| NCT06393751 | Testing the Addition of ASTX660 (Tolinapant) to the Usual Chemotherapy Treatment… | Phase 1 / Phase 2 | withdrawn | May 1, 2024 | National Cancer Institute (NCI) | Other - Protocol moved to Withdrawn | Other (stated, no rule matched) |
| NCT04849364 | Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients…(PERSEVERE) | Phase 2 | terminated | Apr 19, 2021 | Bryan Schneider, MD | Funder Decision | Other (stated, no rule matched) |
| NCT04152018 | Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. | Phase 1 | terminated | Nov 5, 2019 | Pfizer | Study termination was based on strategic considerations and not due to specific safety reasons or a… | Safety / toxicity |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 19, 2025source: clinicaltrials